Abstract
Revascularization procedures used for the treatment of cardiovascular disease can be associated with restenosis, although drug-coated stents have greatly reduced this complication. Both type 2 diabetes (T2DM) and metabolic syndrome (MetS) are associated with a high risk for atherosclerosis and restenosis. Insulin resistance, defined as the inability of insulin to exert its metabolic actions, characterizes both T2DM and MetS. Recent data suggest that insulin resistance is directly implicated in atherosclerosis/restenosis, because of the unresponsiveness to the vasculoprotective action of insulin, including its phosphoinositide 3-kinase (PI3K)-Akt-endothelial nitric oxide synthase mediated enhancement of endothelial function. However, insulin also has ‘atherogenic’ actions, including enhancement of vascular smooth muscle cell (VSMC) proliferation, which are mitogen-activated protein kinase-mediated. These ‘atherogenic’ actions are less affected by insulin resistance, which mainly involves the PI3K pathway. The role of insulin in the atherosclerotic disease process is still highly controversial, where some investigators view insulin as a growth factor with pro-atherogenic effects while some others believe insulin resistance to be pro-atherogenic rather than insulin itself. We attempt to produce a balanced review with a focus on the effect of insulin in vivo, in animal models of atherosclerosis and restenosis.
Keywords: Insulin, restenosis, atherosclerosis, metformin, hypercholesterolemia, hyperinsulinemia, cardiovascular disease, type 2 diabetes mellitus, metabolic syndrome, glucose intolerance, hypertension, thiazolidinediones
Current Vascular Pharmacology
Title: Effects of Insulin on the Vasculature
Volume: 9 Issue: 3
Author(s): Danna M. Breen and Adria Giacca
Affiliation:
Keywords: Insulin, restenosis, atherosclerosis, metformin, hypercholesterolemia, hyperinsulinemia, cardiovascular disease, type 2 diabetes mellitus, metabolic syndrome, glucose intolerance, hypertension, thiazolidinediones
Abstract: Revascularization procedures used for the treatment of cardiovascular disease can be associated with restenosis, although drug-coated stents have greatly reduced this complication. Both type 2 diabetes (T2DM) and metabolic syndrome (MetS) are associated with a high risk for atherosclerosis and restenosis. Insulin resistance, defined as the inability of insulin to exert its metabolic actions, characterizes both T2DM and MetS. Recent data suggest that insulin resistance is directly implicated in atherosclerosis/restenosis, because of the unresponsiveness to the vasculoprotective action of insulin, including its phosphoinositide 3-kinase (PI3K)-Akt-endothelial nitric oxide synthase mediated enhancement of endothelial function. However, insulin also has ‘atherogenic’ actions, including enhancement of vascular smooth muscle cell (VSMC) proliferation, which are mitogen-activated protein kinase-mediated. These ‘atherogenic’ actions are less affected by insulin resistance, which mainly involves the PI3K pathway. The role of insulin in the atherosclerotic disease process is still highly controversial, where some investigators view insulin as a growth factor with pro-atherogenic effects while some others believe insulin resistance to be pro-atherogenic rather than insulin itself. We attempt to produce a balanced review with a focus on the effect of insulin in vivo, in animal models of atherosclerosis and restenosis.
Export Options
About this article
Cite this article as:
M. Breen Danna and Giacca Adria, Effects of Insulin on the Vasculature, Current Vascular Pharmacology 2011; 9 (3) . https://dx.doi.org/10.2174/157016111795495558
DOI https://dx.doi.org/10.2174/157016111795495558 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design Nitrogen and Sulfur Co-doped Fluorescent Carbon Dots for the Detection of Morin and Cell Imaging
Current Analytical Chemistry Features for Heartbeat Sound Signal Normal and Pathological
Recent Patents on Computer Science Molecular Genetics and Targeted Therapy in Hepatocellular Carcinoma
Current Cancer Drug Targets Cell Immunity in Coronary Artery Disease (CAD)
Current Immunology Reviews (Discontinued) Repositioning of HIV Aspartyl Peptidase Inhibitors for Combating the Neglected Human Pathogen Trypanosoma cruzi
Current Medicinal Chemistry Cardioprotective Effects of Natural Products <i>via</i> the Nrf2 Signaling Pathway
Current Vascular Pharmacology Fetuin-A: A Multifunctional Protein
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer
Current Pharmaceutical Design Influence of a High-Fat Diet on Cardiac iNOS in Female Rats
Current Vascular Pharmacology Recent Clinical Aspects of Hyperprolactinemia Induced by Antipsychotics
Reviews on Recent Clinical Trials Urine Albumin/Creatinine Ratio, High Sensitivity C-Reactive Protein and N-Terminal Pro Brain Natriuretic Peptide - Three New Cardiovascular Risk Markers - Do They Improve Risk Prediction and Influence Treatment?
Current Vascular Pharmacology Antioxidants in Peripheral Arterial Disease
Current Drug Targets Atorvastatin Inhibits Advanced Glycation End Products (AGE)-Induced C-Reactive Expression in Hepatoma Cells by Suppressing Reactive Oxygen Species Generation
Vascular Disease Prevention (Discontinued) SAR and QSAR of the Antioxidant Activity of Flavonoids
Current Medicinal Chemistry How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era?
Current Cardiology Reviews Contactless Core-temperature Monitoring by Infrared Thermal Sensor using Mean Absolute Error Analysis
Recent Patents on Engineering Current Paradigms in COVID-19 Research: Proposed Treatment Strategies, Recent Trends and Future Directions
Current Medicinal Chemistry Sterol Biosynthesis Pathway as an Alternative for the Anti-Protozoan Parasite Chemotherapy
Current Medicinal Chemistry Understanding and Avoiding Antiretroviral Adverse Events
Current Pharmaceutical Design